WCLC 2025 - Posters & ePosters-P1.11.20 Camrelizumab-Based Therapy-Induced RCCEP in Advanced NSCLC Patients: A Pooled Analysis of Two Phase III Registration Trials

P1.11.20 Camrelizumab-Based Therapy-Induced RCCEP in Advanced NSCLC Patients: A Pooled Analysis of Two Phase III Registration Trials

Back to course

Pdf Summary

This pooled analysis examined reactive cutaneous capillary endothelial proliferation (RCCEP), a common skin-related immune adverse event, in advanced non-small cell lung cancer (NSCLC) patients treated with camrelizumab-based regimens. Data were combined from two phase 3 trials, CameL and CameL-sq, involving 398 patients with stage IIIB-IV NSCLC (both squamous and non-squamous subtypes). Patients received camrelizumab plus platinum-based chemotherapy, followed by maintenance therapy.<br /><br />RCCEP occurred in 73.4% of patients, mostly mild cases (grade 1 or 2), with only 1.5% experiencing grade 3 severity; treatment discontinuation due to RCCEP was rare (0.5%). The median time to RCCEP onset was 1.48 months. A landmark analysis from this time point showed that patients developing RCCEP had longer camrelizumab exposure and significantly improved clinical outcomes compared to those who did not. Specifically, objective response rates were higher (71.9% vs. 36.8%), median progression-free survival increased (13.01 vs. 6.97 months), and median overall survival was prolonged (31.70 vs. 12.22 months).<br /><br />These findings indicate that RCCEP is a relatively common but manageable dermatologic toxicity in camrelizumab-treated advanced NSCLC patients. Importantly, the occurrence of RCCEP correlates with enhanced treatment efficacy, suggesting RCCEP could serve as a predictive biomarker for response to camrelizumab therapy. Overall, recognizing and monitoring RCCEP may help optimize patient management and prognostication in this setting.

Asset Subtitle

Caicun Zhou

Meta Tag

Speaker Caicun Zhou

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

reactive cutaneous capillary endothelial proliferation

RCCEP

non-small cell lung cancer

NSCLC

camrelizumab

immune-related adverse events

phase 3 clinical trials

progression-free survival

overall survival

predictive biomarker